Hereditary Spastic ParaplegiaNCT05354622
Hereditary Spastic Paraplegia Genomic Sequencing Initiative (HSPseq)
An observational study of Hereditary Spastic Paraplegia and Neurodegenerative Diseases, run by Boston Children's Hospital at 1 site in United States.
Trial summary
The purpose of the HSP Sequencing Initiative is to better understand the role of genetics in hereditary spastic paraplegia (HSP) and related disorders. The HSPs are a group of more than 80 inherited neurological diseases that share the common feature of progressive spasticity. Read more about this study
- Who is it for?
- Ages 1 month to 30 years
- Conditions the study is for
- Hereditary Spastic Paraplegia, Neurodegenerative Diseases, Pediatric Disorder
- How many people
- 200 participants
- Where
- 1 siteUnited States
- Study dates
- 25 Apr 2022to 29 Apr 2027
- How long will I take part?
- 5 Years
- Phase
- Observational
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 1 month to 30 years
- All sexes
- No healthy volunteers
- Child, Adult
Study population: Male or female, under 30 years, with suspected HSP
Who may be able to join
- Clinical diagnosis of progressive spasticity
Who cannot join
None listed.
Trial locations and contacts
1 site in 1 country. Contact the study team or a site near you to ask about taking part.
United States1 site, 1 recruiting
- Recruiting
Boston Children's Hospital
Boston, Massachusetts, 02115
Amy Tam, 617-355-2698, amy.tam@childrens.harvard.edu
About this study
Official title: Investigating the Genetic Basis of Hereditary Spastic Paraplegia
The purpose of the HSP Sequencing Initiative is to better understand the role of genetics in hereditary spastic paraplegia (HSP) and related disorders. The HSPs are a group of more than 80 inherited neurological diseases that share the common feature of progressive spasticity. Collectively, the HSPs present the most common cause of inherited spasticity and associated disability, with a combined prevalence of 2-5 cases per 100,000 individuals worldwide.
In childhood-onset forms, initial symptoms are often non-specific and many children may not receive a diagnosis until progressive features are recognized, often leading to a significant diagnostic delay. Genetic testing in children with spastic paraplegia is not yet standard practice. In this study, the investigators hope to identify genetic factors related to HSP. By identifying different genetic factors, the investigators hope that over time we can develop better treatments for sub-categories of HSP based on cause.
Read the detailed description
The hereditary spastic paraplegias (HSP) are a group of more than 80 inherited neurogenetic diseases that share the common feature of progressive spasticity. Collectively, the HSPs present the most common cause of inherited spasticity and associated disability, with a combined prevalence of 2-5 cases per 100,000 individuals worldwide. In childhood-onset forms, initial symptoms are often non-specific and many children may not receive a diagnosis until progressive features are recognized, often leading to a significant diagnostic delay. Genetic testing in children with spastic paraplegia is not yet standard practice.
The clinical diagnosis of HSP does not suggest anything about its molecular cause, with a wide range of outcomes dependent on the gene affected. The recent advances in HSP genetics speak to the importance of the field and the need for a more detailed study. Moreover, the relations between clinical features and genetic mechanisms are not well understood.
Given the influence of genetics on the likelihood of developing HSP as well as the complexity and diversity of the phenotypes, progress in HSP genetics will require efforts looking at relatively large samples of the HSP population. By bringing together very detailed phenotype information with high resolution DNA analyses, and using new approaches for comparing sequence information in candidate genes or looking for phenotype/genotype associations via genome-wide scanning, the investigators aim to be a leader in this emerging area of HSP research.
The aims of this study include:
- To identify genetic findings (single nucleotide changes or copy number variants) in patients with progressive spastic paraplegia and related disorders.
- To correlate molecular findings with HSP phenotypes.
- Conditions
- Hereditary Spastic Paraplegia, Neurodegenerative Diseases, Pediatric Disorder, Spasticity, Muscle, Motor Neuron Disease, Movement Disorders
- Keywords
- Hereditary Spastic Paraplegia, Neurodegenerative disease, Spasticity, SPG3a, SPG4, SPG11, SPG15, SPG26, SPG47, SPG50, SPG51, SPG52, Complex hereditary spastic paraplegia, Early Onset hereditary spastic paraplegia, Movement disorder, Adaptor protein complex 4, Neurogenetic disorder, Genetic Disease, Muscle Spasticity, Neurodevelopmental disorders
- Medical subject headings
- Spastic Paraplegia, Hereditary, Neurodegenerative Diseases, Muscle Spasticity, Motor Neuron Disease, Movement Disorders, Spastic paraplegia 3, autosomal dominant, Spastic paraplegia 26, autosomal recessive, Genetic Diseases, Inborn
What is being measured
The primary outcome is the main question the study is designed to answer.
Identify Genetic Findings
Identifying genetic variants in patients with progressive spastic paraplegia
Measured: An average of 1 year
Correlating Genetic Findings with HSP Phenotypes
Comparing phenotype/genotype associations via genome wide scanning
Measured: An average of 1 year
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted29 Apr 2022
- Study start25 Apr 2022
- Primary completion29 Apr 2027 (estimated)
- Study completion29 Apr 2027 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Hereditary Spastic ParaplegiaStudies of the same condition, open and under way.
- More trials run by Boston Children's HospitalThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Cohort
- Time perspective
- Prospective
- Enrolment
- 200 participants (estimated)
- Target duration
- 5 Years
Sponsor and investigators
- Lead sponsor
- Boston Children's Hospital
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, Darius Ebrahimi-Fakhari, Boston Children's Hospital
- Investigators
- Darius Ebrahimi-Fakhari, MD, PhD, Principal investigator, Boston Children's Hospital
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT05354622
- Sponsor's protocol ID
- P00039630
- Status last verified
- Mar 2026
- First submitted
- 26 Apr 2022
- Last updated
- 18 Mar 2026
- Results posted
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No